{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976371",
  "id": "02976371",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250804",
  "time": "0907",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhch2k23cnhs.pdf",
  "summary": "- **Clinical Trial Update**:  \n  - **Overall Response Rate (ORR) increased to 79%** (6 Complete Responses, 5 Partial Responses) in Phase 1b trial for **azer-cel CAR T therapy** in relapsed DLBCL.  \n  - **Durability**: First 2024 patient remains cancer-free at 15 months; others show durable responses (3, 7, and 11+ months).  \n  - **High unmet need**: Patients had failed 3\u20136 prior therapies, including autologous CAR-T.  \n  - **Expansion**: Trial now enrolling CAR T-na\u00efve patients with other lymphomas (PCNSL, CLL/SLL, MZL, WM, FL).  \n  - **Next update**: Expected in coming months.  \n\nNo material capital markets or trading-specific information (e.g., raises, halts) identified. Focus is on clinical progress.",
  "usage": {
    "prompt_tokens": 2141,
    "completion_tokens": 191,
    "total_tokens": 2332,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:15:47.926247"
}